CYPHERPUNK TECHNOLOGIES INC. Contract Liability (Deferred Revenue)
CYPHERPUNK TECHNOLOGIES INC. (CYPH) had Contract Liability (Deferred Revenue) of $375.00 thousand as of 2021-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2022-03-11
- 2021-09-30: Contract with Customer, Liability, Current $375.00K.
- 2021-06-30: Contract with Customer, Liability, Current $750.00K.
- 2021-03-31: Contract with Customer, Liability, Current $1.13M.
- 2020-12-31: Contract with Customer, Liability, Current $1.50M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2021-09-30 | $375.00K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $750.00K 10-Q · filed 2021-08-13 |
| 2021-03-31 | $1.13M 10-Q · filed 2021-05-14 |
| 2020-12-31 | $1.50M 10-K · filed 2022-03-11 |
| 2020-09-30 | $1.50M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $1.50M 10-Q · filed 2020-08-13 |
| 2020-03-31 | $1.50M 10-Q · filed 2020-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |